Table 2.
Costs and savings due to the replacement of TIV with QIV by seasons.
| Measure | 2012 season | 2013 season | 2014 season | 2015 season | 2016 season | 2017 season | Total reference case | Total scenario analysis |
|---|---|---|---|---|---|---|---|---|
| % of mismatched cases | 17.5% | 11.2% | 11.2% | 5.9% | 19.9% | 27.9% | ||
| Number of additional events avoided: | ||||||||
| Influenza cases | 337 | 249 | 219 | 221 | 858 | 792 | 2,675 | 13,343 |
| GP consultations | 704 | 517 | 463 | 461 | 1,832 | 1,626 | 5,602 | 10,215 |
| Workdays saved | 1,721 | 1,332 | 1,112 | 1,176 | 4,374 | 4,516 | 14,230 | 38,263 |
| Hospitalizations | 7 | 10 | 6 | 5 | 19 | 22 | 67 | 234 |
| Deaths | 1 | 2 | 1 | 1 | 3 | 3 | 10 | 29 |
| Costs saved, USD | ||||||||
| GP consultations | 38,087 | 27,977 | 25,064 | 24,921 | 99,119 | 87,980 | 303,149 | 552,757 |
| Hospitalizations | 8,606 | 12,006 | 7,018 | 5,973 | 23,567 | 27,267 | 84,437 | 295,012 |
| Productivity losses | 189,475 | 126,255 | 111,465 | 109,102 | 349,302 | 333,196 | 60,925 | 285,062 |
| Costs saved, payer perspective, USD | 46,693 | 39,983 | 32,082 | 30,894 | 122,687 | 115,247 | 387,585 | 847,769 |
| Costs saved, societal perspective, USD | 236,168 | 166,238 | 143,547 | 139,996 | 471,988 | 448,443 | 448,511 | 1,132,830 |
GP = general practitioner; QIV = quadrivalent influenza vaccine; TIV = trivalent influenza vaccine.